within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE10_Darunavir;

model Darunavir
  extends Pharmacolibrary.Drugs.ATC.J.J05AE10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AE10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Darunavir is a protease inhibitor used as part of combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV-1) infection. It is approved for use in adults and children over 3 years old, often co-administered with ritonavir or cobicistat to enhance its pharmacokinetic properties.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy HIV-infected adults after oral administration of darunavir (boosted with ritonavir 100 mg) 800 mg once daily.</p><h4>References</h4><ol><li><p>Kakuda, TN, et al., &amp; Hoetelmans, RM (2014). Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food. <i>Clinical pharmacology in drug development</i> 3(5) 346–352. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.88&quot;>10.1002/cpdd.88</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27129006/&quot;>https://pubmed.ncbi.nlm.nih.gov/27129006</a></p></li><li><p>Rittweger, M, &amp; Arastéh, K (2007). Clinical pharmacokinetics of darunavir. <i>Clinical pharmacokinetics</i> 46(9) 739–756. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200746090-00002&quot;>10.2165/00003088-200746090-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17713972/&quot;>https://pubmed.ncbi.nlm.nih.gov/17713972</a></p></li><li><p>Dickinson, L, et al., &amp; Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>The Journal of antimicrobial chemotherapy</i> 75(3) 628–639. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkz479&quot;>10.1093/jac/dkz479</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31754703/&quot;>https://pubmed.ncbi.nlm.nih.gov/31754703</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Darunavir;
